Latest filings (excl ownership)
20-F
2022 FY
Annual report (foreign)
26 Apr 23
EFFECT
Notice of effectiveness
27 Mar 23
15-12G
Securities registration termination
22 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 23
POS AM
Prospectus update (post-effective amendment)
21 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
21 Mar 23
DEF 14A
Definitive proxy
14 Feb 23
8-K
Entry into a Material Definitive Agreement
31 Jan 23
UPLOAD
Letter from SEC
30 Jan 23
CORRESP
Correspondence with SEC
19 Jan 23
UPLOAD
Letter from SEC
6 Jan 23
CORRESP
Correspondence with SEC
16 Dec 22
UPLOAD
Letter from SEC
7 Dec 22
8-K
Casi Pharmaceuticals Announces Third Quarter 2022 Financial Results
14 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Casi Pharmaceuticals Announces Exit of Juventas Investment to Strengthen Balance Sheet
23 Sep 22
8-K
Casi Pharmaceuticals Announces Second Quarter 2022 Financial Results
12 Aug 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
8-K
Casi Pharmaceuticals Announces Reverse Stock Split
26 May 22
8-K
Other Events
25 May 22
8-K
Submission of Matters to a Vote of Security Holders
25 May 22
8-K
Entry into a Material Definitive Agreement
24 May 22
8-K
Casi Pharmaceuticals Enters into Sublicense Agreement
24 May 22
8-K
Casi Pharmaceuticals Announces First Quarter 2022 Financial Results
12 May 22
10-Q
2022 Q1
Quarterly report
12 May 22
8-K
Other Events
2 May 22
DEF 14A
Definitive proxy
15 Apr 22
PRE 14A
Preliminary proxy
4 Apr 22
8-K
Casi Pharmaceuticals Announces Full-year 2021 Financial Results and Fourth Quarter 2021 Evomela® Revenue
28 Mar 22
10-K
2021 FY
Annual report
28 Mar 22
8-K
Casi Pharmaceuticals Announces Renewal of Exclusive Distribution Agreement for Evomela® In China
4 Mar 22
8-K
Casi Pharmaceuticals Announces Preliminary Fourth Quarter and Full-year 2021 Revenues and Provides Business Updates
16 Feb 22
8-K
Casi Pharmaceuticals, Receives Nasdaq Deficiency Notice
3 Jan 22
8-K
Casi Pharmaceuticals Announces Stock Repurchase Program
17 Dec 21
8-K
Departure of Directors or Certain Officers
10 Dec 21
8-K
Casi Pharmaceuticals Announces Third Quarter 2021 Financial Results
12 Nov 21
10-Q
2021 Q3
Quarterly report
12 Nov 21
Latest ownership filings
SC 13D/A
SPARKLE BYTE LTD
20 Feb 24
SC 13D/A
Ho Chi Sing
21 Feb 23
SC 13G/A
FEDERATED HERMES, INC.
9 Feb 23
SC 13G/A
FEDERATED HERMES, INC.
1 Feb 23
4
Alexander A Zukiwski
9 Sep 22
4
James Huang
8 Sep 22
4
James Huang
2 Sep 22
4
James Huang
26 Aug 22
4
James Huang
23 Aug 22
SC 13D/A
He Wei-Wu
21 Jun 22
4
Wei-Wu He
17 Jun 22
4
Quan Zhou
26 May 22
4
James Huang
26 May 22
4
Yue Alexander Wu
26 May 22
4
RAJESH C MD SHROTRIYA
26 May 22
4
Franklin Cary Salisbury jr
26 May 22
SC 13G/A
Consonance Capital Management LP
14 Feb 22
SC 13G/A
FEDERATED HERMES, INC.
14 Feb 22
4
Alexander A Zukiwski
6 Dec 21
SC 13D/A
He Wei-Wu
23 Nov 21
4
Wei-Wu He
19 Nov 21
4
Wei-Wu He
20 Aug 21
4
Larry Zhang
26 Jul 21
4
Quan Zhou
16 Jun 21
4
Yue Alexander Wu
16 Jun 21
4
RAJESH C MD SHROTRIYA
16 Jun 21
4
Franklin Cary Salisbury jr
16 Jun 21
4
James Huang
16 Jun 21
4
Wei-Wu He
16 Jun 21
SC 13D/A
SPECTRUM PHARMACEUTICALS INC
30 Apr 21
4
Wei-Wu He
30 Mar 21
SC 13G
Consonance Capital Management LP
17 Feb 21
SC 13G
Consonance Capital Management LP
16 Feb 21
SC 13G
FEDERATED HERMES, INC.
12 Feb 21
SC 13D/A
He Wei-Wu
3 Feb 21
4
Wei-Wu He
23 Dec 20
4
Weihao Xu
18 Dec 20
3
Weihao Xu
18 Dec 20
4
Wei-Wu He
24 Nov 20
SC 13D/A
SPECTRUM PHARMACEUTICALS INC
18 Aug 20